TY - JOUR
T1 - Unmet needs in hereditary angioedema
T2 - an international survey of physicians
AU - Buttgereit, Thomas
AU - Aulenbacher, Felix
AU - Adatia, Adil
AU - Ayala, Carolina Vera
AU - Al-Nesf, Maryam Ali
AU - Altrichter, Sabine
AU - Abuzakouk, Mohamed
AU - Al-Ahmad, Mona
AU - Ali, Ramzy Mohammed
AU - Berardi, Alejandro
AU - Boccon-Gibod, Isabelle
AU - Bouillet, Laurence
AU - Brussino, Luisa
AU - Barešić, Marko
AU - Busse, Paula J.
AU - Betschel, Stephen D.
AU - Chong-Neto, Herberto
AU - Llosa, Oscar Calderón
AU - Craig, Timothy J.
AU - Dorr, Anthony D.
AU - Junior, Sérgio Duarte Dortas
AU - Fomina, Daria
AU - Farkas, Henriette
AU - Fok, Jie Shen
AU - Grumach, Anete S.
AU - Greve, Jens
AU - Guilarte, Mar
AU - Gonçalo, Margarida
AU - Grivcheva-Panovska, Vesna
AU - Hide, Michihiro
AU - Hakl, Roman
AU - Jindal, Ankur
AU - Katelaris, Constance H.
AU - Kamaleswaran, Shailajah
AU - Kinaciyan, Tamar
AU - Latysheva, Elena
AU - Sousa, José Ignacio Larco
AU - Bellfill, Ramón Lleonart
AU - Mobayed, Hassan
AU - Metz, Martin
AU - Nasr, Iman
AU - Mitrevska, Natasa T.
AU - Nicola, Stefania
AU - Parisi, Claudio Alberto Salvador
AU - Porebski, Grzegorz
AU - Peter, Jonny
AU - Ferriani, Mariana Paes Leme
AU - Filho, Nelson Rosario
AU - Şekerel, Bülent Enis
AU - Serpa, Faradiba Sarquis
PY - 2025
Y1 - 2025
N2 - Background: Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic disorder characterized by unpredictable attacks of angioedema. MENTALIST (UnMEt Needs in herediTAry angioedema—a gLobal physIcian perSpecTive) is the first international survey uncovering unmet needs and identifying barriers to optimal management in HAE following the latest update of the World Allergy Organization (WAO)/European Academy of Allergy and Clinical Immunology (EAACI) HAE guidelines. Methods: This web-based survey comprised 24 questions on HAE management and unmet needs. HAE-expert physicians from the Angioedema Centers of Reference and Excellence network ranked unmet needs according to their own perspectives and their patients’ perspectives, using a 10-point Likert scale ranging from 0 (not a challenge/unmet need at all) to 10 (huge challenge/unmet need). Results: Of 64 respondents from 32 countries, most (91%) had > 5 years of experience in managing HAE. Overall, 48% of respondents (n = 31/64) reported that < 50% of their patients had achieved the WAO/EAACI HAE treatment goals of total disease control and “normalization” of life at the time of the survey. Implementation of consensus recommendations was found to be inconsistent across regions. Gaps in non–HAE-expert physician knowledge, treatment costs, and reimbursement for long-term prophylaxis were the highest-priority challenges according to the respondents. Burden of disease remains a challenge among patients, as reported by their physicians. Conclusions: The MENTALIST findings highlight a need for removal of barriers to HAE treatment goals and propose a call to action to improve access to treatments, for greater provision of education for physicians and patients, critical collaboration with patient organizations and industry stakeholders and ultimately to optimize HAE care.
AB - Background: Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic disorder characterized by unpredictable attacks of angioedema. MENTALIST (UnMEt Needs in herediTAry angioedema—a gLobal physIcian perSpecTive) is the first international survey uncovering unmet needs and identifying barriers to optimal management in HAE following the latest update of the World Allergy Organization (WAO)/European Academy of Allergy and Clinical Immunology (EAACI) HAE guidelines. Methods: This web-based survey comprised 24 questions on HAE management and unmet needs. HAE-expert physicians from the Angioedema Centers of Reference and Excellence network ranked unmet needs according to their own perspectives and their patients’ perspectives, using a 10-point Likert scale ranging from 0 (not a challenge/unmet need at all) to 10 (huge challenge/unmet need). Results: Of 64 respondents from 32 countries, most (91%) had > 5 years of experience in managing HAE. Overall, 48% of respondents (n = 31/64) reported that < 50% of their patients had achieved the WAO/EAACI HAE treatment goals of total disease control and “normalization” of life at the time of the survey. Implementation of consensus recommendations was found to be inconsistent across regions. Gaps in non–HAE-expert physician knowledge, treatment costs, and reimbursement for long-term prophylaxis were the highest-priority challenges according to the respondents. Burden of disease remains a challenge among patients, as reported by their physicians. Conclusions: The MENTALIST findings highlight a need for removal of barriers to HAE treatment goals and propose a call to action to improve access to treatments, for greater provision of education for physicians and patients, critical collaboration with patient organizations and industry stakeholders and ultimately to optimize HAE care.
KW - Guidelines
KW - Hereditary angioedema
KW - Management
KW - Treatment goals
KW - Unmet needs
UR - http://www.scopus.com/inward/record.url?scp=105012460590&partnerID=8YFLogxK
U2 - 10.1186/s13023-025-03739-8
DO - 10.1186/s13023-025-03739-8
M3 - Article
C2 - 40722187
AN - SCOPUS:105012460590
SN - 1750-1172
VL - 20
JO - Orphanet Journal of Rare Diseases
JF - Orphanet Journal of Rare Diseases
IS - 1
M1 - 383
ER -